Abstract: This invention relates to skin pore tighteners each of which comprises, as an active ingredient, a compound represented by the following formula: R1—OG ??(1) wherein R1 represents an alkyl or alkenyl group having 8 to 32 carbon atoms, and OG represents a residual group obtained by removing a hydrogen atom from a hydroxyl group of a polyhydric alcohol, monosaccharide or oligosaccharide at least one hydroxyl group of which has been sulfated or phosphatized, or a salt thereof, and also to skin elasticity improvers each of which comprises, as an active ingredient, a glyceryl ether derivative represented by the following formula: wherein R1 represents the same group as defined above, and X1 and X2 each independently represents a hydrogen atom, —SO3OH or —PO(OH)2 with the proviso that X1 and X2 are not hydrogen atoms at the same time, or a salt thereof.

Abstract: The invention relates to a method for hatching of hatchery eggs comprising: (a) treating the egg shell surface with a coating composition comprising a coating agent, to form a coating on the surface of the egg's shell; and (b) incubating the egg under conditions to cause hatching to occur; wherein the yield of hatching of said hatchery eggs is improved as compared to control eggs not treated as defined in (a). The invention additionally relates to a composition for treating of hatchery eggs prior to incubation, wherein said composition comprising a coating agent, and wherein said composition improves the hatching yield of said hatchery eggs.

Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.

Abstract: The present invention refers to a process for bacterial stabilizing aqueous preparations like e.g. calcium carbonate slurries and a composition which can be used for the biocidal treatment of such aqueous preparations.

Abstract: Disclosed is a water-soluble colonoscopy lubricant essentially comprising Polyethylene Glycol 400; Propylene Glycol; and Glycerin. Distilled water may be added as needed to achieve a desired viscosity. Additional ingredients such as a preservative and a pH adjuster may also be added to the colonoscopy lubricant.

Abstract: The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paraesthesia of the synthetic pyrethroid. The system releases the synthetic pyrethroid efficiently and uniformly. The pest control system is less irritating to the animal's skin as compared to prior art systems, particularly to the small breeds of dogs. The system is useful for making liquid spot-on treatments, sprays and the like.

Abstract: A lotion composition applied on the body facing surface of an absorbent article such as a diaper, training pant, adult incontinence product, feminine hygiene product, improves the ease of removal of feces or menses after an absorbent article comprising the lotion composition has been used and removed from the wearer. The lotion composition may also suitably be applied on a wipe.

Abstract: The present invention relates to a method of producing wax/oil-in-water (O/W) dispersions of self-emulsifying O/W gel concentrates without stirring or in a laminar flow field.

Abstract: An oil-in-water microemulsion is provided, which includes, on the basis of its total weight, the following components of A) 55-95 wt % of a water phase; B) 0.1-20 wt % of an oil phase, wherein the oil phase comprises at least one oil/fat component containing polyoxypropylene chains; and C) 1-25 wt % of an oil-in-water nonionic emulsifier, wherein the emulsifier is selected from the following group of: hydrophilic nonionic surfactants with polyoxyethylene chains as hydrophilic groups, polyglycerol fatty acid esters, polyglycerol fatty alcohol ethers, sucrose fatty acid esters, and hydrocarbyl polyglycosides. The oil-in-water microemulsion carries a large amount of oil. In addition, the use of an oil/fat containing polyoxypropylene chains is disclosed for increasing the amount of oil carried in an oil-in-water microemulsion.

Abstract: Polyalkylene oxide derivates of the formula (I), in which the symbols and indices have the following meanings: Ra is a C8-C30-hydrocarbon radical; Rb is a C8-C30-hydrocarbon radical, such as C8-C30-alkyl, C8-C30-alkenyl, C8-C30-alkynyl; a is 0 or 1; b is 0 or 1; c is 0 or 1 and A is one or more alkylene oxide units. Compounds of the present invention are suitable for promoting the penetration of insecticidal active substances into plants.

Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.

Abstract: A method of improving heart function in a subject, the method comprising administering an effective amount of a hyperbranched polyglycerol to a subject. The improvement in heart function may include one or more of an increase in myocardial contractile function, reduced or absent fibrosis, an increase in mechanical efficiency of the heart, an increase in ejection fraction, an increase in glucose oxidation or a decrease in fatty acid oxidation, as determined by conventional methods known in the art.

Abstract: Methods, devices, and remediation compositions for the microwave remediation of medical wastes are provided. The remediation compositions include a microwave active fluid including a microwave active liquid, a microwave enhancer, and a viscosity modifying agent. Methods include immersing medical waste in the remediation composition and then irradiating the medical waste and the remediation composition to remediate the medical waste. The devices include a container for the medical waste and the remediation composition, a microwave radiation source and a temperature monitoring device.

Abstract: A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.

Abstract: A colon prep method and kit for facilitating a method for evacuating a colon prior to a medical procedure, wherein the method minimizes potential patient discomfort. Three selected meals and a plurality of selected snacks are ingested on a day prior to the medical procedure. The meals include solid food items taken with or incorporating a stimulant laxative, such as senna, incorporated therein. A liquid having a PEG laxative, such as PEG-3350, is provided with or incorporated therein, preferably via a powdered drink mix. The stimulant laxative and the PEG laxative work in synergy. A further optional snack may be provided on the day of the medical procedure, preferably ingested approximately four hours before the medical procedure.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.

Abstract: An antimicrobial composition for use as a disinfectant or a preservative. The disinfectant may be used in disinfecting and cleaning surfaces. The preservative is particularly useful in personal care and cosmetic products, and pharmaceuticals. The composition includes a base component and an alkyl mono propylene glycol ether, an alkyl mono glycerol ether, or a combination of these ethers. The base component may be water, alcohol, lotion, cream, shampoo, soap, cosmetic color agent, hair conditioner, lip balm, and face, eye or lip make up, ointment.

Abstract: According to an aspect of the invention, a polymerized form of formaldehyde is available in granular form containing a polymerized form of formaldehyde, such as paraformaldehyde, a buffer, such as sodium phosphate dibasic anhydrous, and a stabilizer, such as hydroxymethyl cellulose, or hydroxypropyl methyl cellulose. When added to an aqueous solvent, the paraformaldehyde can dissolve in alkaline solution, and depolymerizes into a formaldehyde solution containing a stabilizer. Optionally a second member of the buffer pair or another buffer or pH adjuster can be used The stabilized depolymerized formaldehyde solution is then ready for use, or can be modified by addition of other substances, such as sodium phosphate monobasic monohydrate. Additionally, an additional buffer may be included in the granular mixture to increase the rate at which the solid dissolves and depolymerizes.

Abstract: It is to provide a compound which has a low vapor pressure and low viscosity, which is less problematic in deterioration during its use and which is useful as e.g. a lubricant, a surface modifier or a surfactant. A fluoropolyether compound represented by the formula (X—)xY(—Z)z, wherein X is a group represented by the formula HO—(CH2CH2O)a.(CH2CH(OH)CH2O)b—(CH2)c—CF2O(CF2CF2O)d— (wherein “a” is an integer of from 0 to 100, b is an integer of from 0 to 100, c is an integer of from 1 to 100, and d is an integer of from 1 to 200), Z is a group represented by the formula RFO(CF2CF2O)g— (wherein RF is e.g. a C1-20 perfluoroalkyl group having an etheric oxygen atom inserted between carbon-carbon atoms, and g is an integer of from 3 to 200), Y is e.g. a (x+z) valent perfluorinated saturated hydrocarbon group, x is an integer of at least 2, z is an integer of at least 0, and (x+z) is an integer of from 3 to 20.

Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Abstract: The present invention is to provide a new compound having a rough skin improving effect, excellent in safety, excellent in texture in use, especially free of sticky feeling, excellent in refreshing feeling, and capable to improve the base agent stability as a component. An alkylene oxide derivative is characterized by being represented by the below-described general formula (I): (formula I) Z-{O-[(AO)a-(EO)b]-R}2??(I) (In the formula, Z is the residue obtained by removing hydroxyl groups from the dimer diol, EO is an oxyethylene group, AO is an oxyalkylene group having 3 to 4 carbon atoms, and the addition form is block-type. The symbols a and b are the average addition mole numbers of the above-described oxyalkylene group and the oxyethylene group, respectively, and they are 1?2 a?150 and 1?2 b?150. The percentage of the oxyethylene groups with respect to the sum of the oxyalkylene groups having 3 to 4 carbon atoms and the oxyethylene groups is 10 to 99 mass %.

Abstract: This invention relates to therapeutic compositions comprising a surface active copolymer, such as poloxamer-188, in an amount effective to enhance microvascular blood flow and/or inflammation in injured skin or other tissue, and methods of using the therapeutic compositions of the invention to inhibit decreased blood flow associated with an injury, disease, or disorder.

Abstract: A method of facilitating intracellular uptake or transcellular transport of cargo comprising: contacting target cells with a composition comprising an effective amount of cargo incorporated in a nanocarrier having a surface, wherein the nanocarrier surface comprises integrin-specific ligands having a surface density of approximately 5 to 50,000 integrin-specific ligands per ?m2, and maintaining contact between the composition and the target cells for a period of time sufficient to permit intracellular uptake or transcellular transport of the cargo.

Abstract: The invention relates to compounds, which are suitable for coupling to pharmaceuticals, in particular biopharmaceuticals, in addition to conjugates from the compounds comprising biomolecules or pharmaceutically active substances. The inventive compounds are highly cross-linked and can be formed in a simple manner by using a central cross-linking module. The invention also relates to the use of conjugates as an improved formulation of pharmaceuticals and to the production thereof.

Abstract: A compound comprising Formula I, or a mixture thereof, Rf—OCFHCF2O—[CH2CH2O]x—[C3H7O]y-A??Formula I wherein Rf is CnF2n+1, n is 1 to about 6, x is a mixture of positive integers and is 4 or greater, y is 0 to about 4, provided that the ratio of y to x is equal to or less than 0.25, A is RfOCHFCF2 or CmH2m+1, and m is 1 to about 24 and its use in lowering surface tension and imparting improved surface effects is disclosed.

Abstract: The deodorized, polyether-modified polysiloxane composition not producing a substance giving off a foul odor, while being produced or stored, which results from hydrolysis, oxidation or the like of a by-product or unreacted material and temporarily stable, a method for producing the same, and a cosmetic containing the same, wherein a polyether-modified polysiloxane composition, synthesized by hydrosilylation in which a polyoxyalkylene having the carbon-carbon double bond at the terminal is reacted with an organohydrogen polysiloxane, is refined by treatment in the presence of a solid acid.

Abstract: A device and a method for generating therapeutic foam from a sclerosing solution such as polidocanol and a gas which is absorbable or dissolvable in the body comprises a disposable cassette including a liquid container and a flexible chamber containing gas, chamber being formed as a loop. Located in the loop chamber is a foam generating mesh. In use, liquid is introduced into the chamber and then the cassette is inserted into a pumping machine where it is engaged by a peristaltic pump which circulates the contents of the loop chamber through the mesh, thus creating foam. When a steady state is reached, foam may be withdrawn using a syringe via either a port or septum.

Abstract: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.

Abstract: A method of protecting hair by covalently bonding to the hair a polymeric compound comprising polyethylene glycol.

Abstract: Disclosed are hydrogel compositions formed by the mixture of a tetramethylmethane substituted with one or more polyethylene glycols, and wherein each polyethylene glycol substituent is independently further substituted with one or more electrophilic groups, and a tetramethylmethane substituted with one or more polyethylene glycols, and wherein each polyethylene glycol substituent is independently further substituted with one or more nucleophilic groups. Disclosed are also methods of preparing the above hydrogels. The hydrogel compositions can further comprise pharmaceuticals, such as analgesics or local anesthetics. Disclosed are also methods of sealing a wound, preventing post-surgical adhesion, and reducing post-surgical pain using the disclosed hydrogels.

Abstract: The present invention relates to hydrogel compositions or aqueous solutions comprising one or more forms of Poly-ethylene Glycol, for use as medicaments, more particularly for topical application in the treatment of wounds, for the treatment of inflammatory skin disease and in particular for the prevention of scar formation and/or for enhancing the repair of damaged skin or mucosa.

Abstract: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.

Abstract: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has had to be made heretofore. This invention describes a low volume, hyper-osmotic solution consisting of sulfate salts with and with out polyethylene glycol, and further comprising a sweetener and/or flavoring. Unlike prior art, this composition is useful for the cleansing of the bowel and, in lower volumes, as a laxative, without producing clinically significant changes in bodily function.

Abstract: Disclosed is a lamellar liquid crystal composition for cosmetic use, which contains one or more polyglycerol monoethers and has a lamellar liquid crystalline phase formed by the polyglycerol monoethers. The polyglycerol monoethers each have a hydrophile-lipophile balance (HLB) of 6 to 12 and are represented by following Formula (I): RO-(GL)n-H ??(I) wherein R represents a linear or branched alkyl, alkenyl, or hydroxyalkyl group; “n” denotes an integer of from 2 to 10; and GL represents a glycerol unit. The cosmetic composition exhibits a superior cleansing power regardless of whether the skin is wet or not, and gives a satisfactory feel during use without leaving an oily sensation after rinsing with water.

Abstract: Topical compositions comprising: —a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to (8) carbon atoms; —water; and—optionally an unsaturated fatty alcohol; and optionally further conventional excipients, for use as a cosmeceutical, in particular for use in the repair or maintenance of skin barrier function. They are indicated for use in e.g. moisturizing skin, nail and mucosa and, when an optional pharmaceutically active agent is present, additionally in the treatment of various skin, nail and mucosal diseases. Also disclosed are compositions suitable for topical application to infants and babies for treating dry skin, and soothing skin irritated from diaper rash and scrapes.

Abstract: Methods of treating an injured vertebrate spinal cord are described. In one aspect of the invention, a method of treating an injured vertebrate spinal cord includes contacting the spinal cord with a biomembrane fusion agent such as a polyalkylene glycol, especially polyethylene glycol. In alternative embodiments of the invention, methods of treating an injured vertebrate spinal cord include contacting the cord with a biomembrane fusion agent and a potassium channel blocker. Other aspects of the invention include compositions for treating a vertebrate nervous system. A preferred composition includes a biomembrane fusion agent, such as a polyalkylene glycol, and a potassium channel blocker, such as an amino-substituted pyridine.

Abstract: The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial pathogen. Methods for preventing and treating cell disorders, such as epithelial cell disorders including gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly, Pseudomonas-mediated opthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection, using the modulators are contemplated, as are methods for ameliorating a symptom associated with such a disorder.

Abstract: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Abstract: The invention concerns a process for producing a preserved customised consumer composition, preferably from a Vending machine, wherein a plurality of ingredient streams are mixed together in predefined relative amounts, characterised in that At least two streams consist of water and preservative only, at least two of which having different concentrations of preservative. The Invention permits the final preservative mix to be independently variable to the formation.

Abstract: A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Abstract: Methods of repairing or augmenting soft tissue in a subject are described. The methods include injecting into a subject composition comprising a biodegradable, polymerizable macromer, the macromer comprising a water soluble polymer modified with one or more biodegradable moieties; and polymerizing the macromer to provide a hydrogel, thus repairing or augmenting the soft tissue.

Abstract: This invention relates to skin pore tighteners each of which comprises, as an active ingredient, a compound represented by the following formula: R1—OG ??(1) wherein R1 represents an alkyl or alkenyl group having 8 to 32 carbon atoms, and OG represents a residual group obtained by removing a hydrogen atom from a hydroxyl group of a polyhydric alcohol, monosaccharide or oligosaccharide at least one hydroxyl group of which has been sulfated or phosphatized, or a salt thereof, and also to skin elasticity improvers each of which comprises, as an active ingredient, a glyceryl ether derivative represented by the following formula: wherein R1 represents the same group as defined above, and X1 and X2 each independently represents a hydrogen atom, —SO3OH or —PO(OH)2 with the proviso that X1 and X2 are not hydrogen atoms at the same time, or a salt thereof.

Abstract: Provided is an aqueous liquid detergent composition containing a long-chain fatty acid glycol ester represented by the following formula (1): R1COO(CH2CH2O)mA ??(1) wherein, A is H or COR2, R1 and R2 represents a C11-21 alkyl or alkenyl group, and m stands for a number of from 1 to 3, and a surfactant, wherein the fatty acid constituent of the long-chain fatty acid glycol ester contains 60 wt. % or greater of fatty acids having 18 or more carbon atoms, 40 wt. % or less of a fatty acid having 16 carbon atoms, and 5 wt. % or less of fatty acids having less than 16 carbon atoms; and the composition has a pH of from 1 to 5 at 25° C. when diluted to 20 times the weight with water. The detergent composition has benefits such as an elegant and expensive-looking pearl luster, is excellent in stability of a pearling agent, particularly long storage stability at high temperatures, and has good detergency and foaming property.

Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.

Abstract: The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula: HO(C2H4O)b(C3H6O)a(C2H4O)bH wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: According to the first aspect of the invention, a composition for reversing malarial resistance to quinolines is disclosed. The composition includes a surfactant, such as nonylphenolethoxylate (NPE) in an admixture with a pharmaceutically acceptable carrier, excipient, or diluent. According to a second aspect of the invention, a composition for the prevention or treatment of malaria is provided. The composition comprises a pharmaceutically effective amount of a quinoline in combination with a surfactant, such as NPE, for reversing malarial resistance to quinolines. According to a third aspect of the invention, a method of preventing or treating malaria in a person is provided. The method comprises administering to a patient in need thereof one or both of the compositions described above.

Abstract: A method comprising administering by ocular route a dose of a glycol ether effective to induce retinal detachment.